阿瑞吡坦预防肺癌患者含顺铂化疗的止吐疗效观察

目的观察阿瑞吡坦预防肺癌患者含顺铂化疗的止吐疗效和安全性。方法肺癌患者72例随机分为阿瑞吡坦治疗组36例和安慰剂组36例，两组患者均同时接受昂丹司琼＋地塞米松治疗。观察急性（第1天）及延迟性（第2～5天）呕吐控制情况和不良反应。结果阿瑞吡坦组呕吐控制率为67．2％，高于安慰剂组54．3％（P〈0．05），延迟期亦高于安慰剂组（70.5％vs55.4％，P〈0.05），急性期两组比较差异无统计学意义（78.5％vs77.4％，P〉0．05）。结论阿瑞吡坦可以有效预防肺癌患者含顺铂化疗延迟性呕吐，且不良反应小。

Objective To assess the antiemetic efficacy and safety of aprepitant in patients with lung cancer receiving cisplatin chemotherapy. Methods Seventy-two patients with hmg cancer were randomly divided into treatment group of aprepitant （ n=36 ） and placebo group （ n=36 ） , and all of them received ondansetron plus dexamethasone treatment. Acute （ at 1 day ） and delayed （ at 2-5 days ） antiemetic efficacy and adverse effects were observed. Results The total antiemetic rate in treatment group （ 67.2% ） was significantly higher compared with that in placebo group （ 54.3%, P〈0.05 ） . In the delayed period, it was significantly higher in treatment group than in placebo group （ 70.5% vs 55.4%, P〈0.05 ） , while there was no statistical difference between two groups in acute period （ 78.5% vs 77.4%, P〉0.05 ） . Conclusion Aprepitant can effectively prevent lung cancer patients receiving cisplatin chemotherapy from acute and delayed vomiting, with few adverse reactions.